Literature DB >> 1777368

The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

T L Schwinghammer1, D Przepiorka, R Venkataramanan, C P Wang, G J Burckart, C S Rosenfeld, R K Shadduck.   

Abstract

1. The pharmacokinetics of cyclosporine (CsA) and the time course of CsA metabolites were studied in five bone marrow transplant patients after intravenous (i.v.) administration on two separate occasions and once after oral CsA administration. 2. Cyclosporine and cyclosporine metabolites were measured in whole blood by h.p.l.c. 3. Cyclosporine clearance after i.v. administration decreased from 3.9 +/- 1.7 ml min-1 kg-1 to 2.0 +/- 0.6 ml min-1 kg-1 after 14 days of treatment. The mean +/- s.d. absolute oral bioavailability of cyclosporine was 17 +/- 11%. 4. Hydroxylated CsA (M-17) was the major metabolite in blood. There were no significant differences in the mean metabolite/CsA AUC ratios between the first and second i.v. studies. 5. After oral administration, the metabolite to CsA AUC ratios were higher for most metabolites compared to those observed in the second i.v. study, suggesting a contribution of intestinal metabolism to the clearance of CsA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777368      PMCID: PMC1368525          DOI: 10.1111/j.1365-2125.1991.tb03906.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Sensitivity of activated human lymphocytes to cyclosporine and its metabolites.

Authors:  A Zeevi; R Venkataramanan; G Burckart; C P Wang; N Murase; D H Van Thiel; T E Starzl; L Makowka; R J Duquesnoy
Journal:  Hum Immunol       Date:  1988-02       Impact factor: 2.850

2.  Biotransformation and distribution in blood of cyclosporine and its metabolites.

Authors:  G Maurer; M Lemaire
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 3.  Metabolism of cyclosporine.

Authors:  G Maurer
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

4.  Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells.

Authors:  A Zeevi; G Eiras; G Burckart; L Makowka; R Venkataramanan; C P Wang; D H Van Thiel; N Murase; T E Starzl; R Duquesnoy
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Interaction between phenytoin and cyclosporine following organ transplantation.

Authors:  P A Keown; A Laupacis; G Carruthers; M Stawecki; J Koegler; F N McKenzie; W Wall; C R Stiller
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

6.  The effects of cyclosporin A (CsA) on hepatic microsomal drug metabolism in the rat.

Authors:  J A Augustine; M A Zemaitis
Journal:  Drug Metab Dispos       Date:  1986 Jan-Feb       Impact factor: 3.922

Review 7.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

8.  Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction.

Authors:  K Atkinson; J C Biggs; K Britton; R Short; R Mrongovius; A Concannon; A Dodds
Journal:  Br J Haematol       Date:  1984-02       Impact factor: 6.998

9.  Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients.

Authors:  T G Rosano; B M Freed; J Cerilli; N Lempert
Journal:  Transplantation       Date:  1986-09       Impact factor: 4.939

10.  In vitro immunosuppressive properties of cyclosporine metabolites.

Authors:  B M Freed; T G Rosano; N Lempert
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

View more
  10 in total

1.  Interaction between FK 506 and cyclosporine in dogs.

Authors:  Y M Wu; R Venkataramanan; M Suzuki; Y Zhu; H Abdallah; J Emeigh; G J Burckart; V S Warty; J J Fung; S Todo
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 2.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.

Authors:  Abraham J Wilhelm; Peer de Graaf; Agnes I Veldkamp; Jeroen J W M Janssen; Peter C Huijgens; Eleonora L Swart
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

4.  Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

Authors:  I R Webber; W H Peters; D J Back
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 5.  Population pharmacokinetics of cyclosporine in transplant recipients.

Authors:  Kelong Han; Venkateswaran C Pillai; Raman Venkataramanan
Journal:  AAPS J       Date:  2013-06-18       Impact factor: 4.009

6.  Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors.

Authors:  Yuichiro Nawa; Masamichi Hara; Kazushi Tanimoto; Koichi Nakase; Teruhiko Kozuka; Yoshinobu Maeda
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 7.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

8.  Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.

Authors:  Michael Gertz; Catherine M Cartwright; Michael J Hobbs; Kathryn E Kenworthy; Malcolm Rowland; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

9.  Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin.

Authors:  Cyrus R Kumana; Matthew K L Tong; Chun-Sang Li; Ian J Lauder; Joseph S K Lee; Maybelle Kou; Tom Walley; Alan Haycox; Tak Mao Chan
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 10.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.